Literature DB >> 2990691

Epidemiology of human lymphotrophic retroviruses: an overview.

W A Blattner, R J Biggar, S H Weiss, J W Clark, J J Goedert.   

Abstract

The discovery of HTLV-I opened the way for the subsequent recognition of other human retroviruses. HTLV-I is linked to an aggressive T-cell cancer. The availability of a marker for the AIDS agent, HTLV-III, has substantially enhanced our ability to define the nature of the AIDS epidemic, its clinical and subclinical manifestations, and the spectrum of disease outcomes associated with this exposure. Of particular interest is the fact that there is substantial risk for AIDS and AIDS-related outcomes in virally infected individuals as detected by antibody positivity. The preliminary data from these well defined cohorts provide a basis for estimating the enormity of the AIDS epidemic as it is starting to emerge and provide an opportunity for the forward thinking health strategies necessary for dealing with a pandemic of such proportions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990691

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Adult T-cell leukemia-lymphoma.

Authors:  S M Neely
Journal:  West J Med       Date:  1989-05

2.  T-helper phenotype chronic lymphocytic leukemia (Thp-CLL): characterization of an Italian case with particular biological findings.

Authors:  D Pasqualetti; A Cafaro; R Gastaldi; M Lopez; F Malagnino; V Manzari; G De Rossi
Journal:  Blut       Date:  1987-05

3.  Chromosomal abnormalities in adult T-cell leukemia/lymphoma (ATL). A report of six cases with review of the literature.

Authors:  R S Verma; M J Macera; M Krishnamurthy; J Abramson; S Kapelner; H Dosik
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

4.  AIDS epidemiology: inconsistencies with human immunodeficiency virus and with infectious disease.

Authors:  P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.